Kevin Marks is the CEO & President of Delphia Therapeutics, a next-generation precision medicine company pioneering activation lethality to improve cancer care. Kevin formed Delphia as an entrepreneur in residence at GV.

Before joining GV in 2022, Kevin spent nearly 20 years as a cancer drug hunter in diverse settings across the biotech and pharma sectors. Previously, he led a broad team of oncology scientists to advance an innovative portfolio of first-in-class medicines as Head of Oncology Drug Discovery at Novartis in Cambridge, MA. Before Novartis, Kevin was an early employee at multiple biotech companies, including Agios Pharmaceuticals, where he championed advances in the science, organization, and culture over a decade-long tenure that culminated in his role as Vice President and Head of Biology.

Kevin holds a B.A. in Cell Biology from Cornell University and a Ph.D. in Molecular Pharmacology from Stanford University.